Public University Corporation Nagoya City University

National Institute of Advanced Industrial Science and Technology

National Center for Global Health and Medicine

Toray Industries, Inc.

Sysmex Corporation

Nagoya University

Fujifilm Toyama Chemical Co., Ltd.

National Institute of Infectious Diseases

Glycobiomarker Leading Innovation Co., Ltd.

Nagoya City University

Yasuhito Tanaka

Masashi Mizokami

Hisashi Narimatsu

Yuzuru Ikehara

Atsushi Kuno

Maki Sogabe

Takaji Wakita

Jun Hirabayashi

Tomoko Date

Akira Togayachi

Hiroyuki Kaji

Shinya Nagai

Youichi Takahama

Chikayuki Tsuruno

Takashi Ohkura

Kiyoaki Ito

Takashi Angata

Shunsuke Matsubara

Takashi Kagawa

Kazuki Shimane

Kentaro Matsuura

Toshihide Shikanai

Makoto Ochou

Shigeru Kusumoto

The present invention addresses the problem of how to provide a predictive marker useful for carcinogenesis surveillance after hepatitis C virus eradication. Provided is a predictive marker composed of a single nucleotide polymorphism specified by rs17047200. In the present invention, the single nucleotide polymorphism is detected in nucleic acid samples collected from subjects, thereby to examine the risk of developing hepatocellular carcinoma after of hepatitis C virus eradication.

Prediction of hepatocellular carcinoma onset after clearance of hepatitis C virus

An anti-hepatitis B virus agent comprising a compound represented by general formula [1], 

Anti-hepatitis B virus agent

The present invention is directed to developing a glycan markers capable of detecting a hepatic disease, and more specifically to developing a glycan marker indicating a hepatic disease-state. Furthermore, the present invention is also directed to developing a glycan marker capable of distinguishing hepatic disease-states with the progress of hepatocarcinoma. The present inventors identified, among the serum glycoproteins, glycopeptides and glycoproteins in which a glycan structure specifically changes due to a hepatic diseases including hepatocarcinoma and provide these as novel glycan markers (glycopeptide and glycoprotein) specific to hepatic disease-states.

Glycan markers as measure of disease state of hepatic diseases

A subgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and a fullgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and infectious HCV particle-producing ability, each derived from a novel HCV of genotype 1b, are provided. Particularly, a subgenomic replicon RNA (nucleic acid) and a fullgenomic replicon RNA (nucleic acid), each derived from an HCV genome of the NC1 strain which is a novel HCV genotype 1b isolated from a patient with acute severe hepatitis C, are provided.

Nucleic acid construct comprising nucleic acid derived from genome of hepatitis C virus of genotype 1B, hepatitis C virus genome-replicating cells transfected with the same, and method for producing infectious hepatitis C virus particles

An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Disclosed is a method for measuring at least one glycoprotein selected from alpha-1-acid glycoprotein (AGP) and Mac-2-binding protein (M2BP) contained in a sample collected from a subject, comprising: measuring AGP binding to a first lectin selected from AOL and MAL, when the glycoprotein is AGP; and measuring M2BP binding to a second lectin selected from WFA, BPL, AAL, RCA120, and TJAII, when the glycoprotein is M2BP.

Method for measuring glycoprotein, method for examining liver disease, reagent for quantitative determination of glycoprotein, and glycan-marker glycoprotein as an index for clinical conditions of liver disease

Growing community of inventors

Aichi, Japan

Yasuhito Tanaka